Press release
Adrenocortical Carcinoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Adrenocortical Carcinoma Pipeline Report
* In May 2025, Corcept Therapeutics conducted a study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
* DelveInsight's Adrenocortical Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment.
* The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
* Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Adrenocortical Carcinoma Emerging Drugs Profile
* Relacorilant: Corcept Therapeutics
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing's syndrome and advanced adrenal, ovarian and pancreatic cancer.
* Ipilimumab: Bristol-Myers Squibb
Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma.
The Adrenocortical Carcinoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
* Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market
Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Adrenocortical Carcinoma Drugs [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Adrenocortical Carcinoma Companies
Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Adrenocortical Carcinoma Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Adrenocortical Carcinoma Market Report
* Coverage- Global
* Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
* Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
* Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Adrenocortical Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Adrenocortical Carcinoma- DelveInsight's Analytical Perspective
* Mid Stage Products (Phase II)
* Ipilimumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Relacorilant: Corcept Therapeutics
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Adrenocortical Carcinoma Key Companies
* Adrenocortical Carcinoma Key Products
* Adrenocortical Carcinoma- Unmet Needs
* Adrenocortical Carcinoma- Market Drivers and Barriers
* Adrenocortical Carcinoma- Future Perspectives and Conclusion
* Adrenocortical Carcinoma Analyst Views
* Adrenocortical Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adrenocortical-carcinoma-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenocortical Carcinoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4026999 • Views: …
More Releases from ABNewswire
"Dante's London Bridge" by Peter Prizel Delivers a Haunting Blend of Time Travel …
Dante's London Bridge by Peter Prizel is a haunting, genre-blending novel of time travel, historical mystery, and spiritual redemption. When a young scholar uncovers a forgotten manuscript beneath London Bridge, messages, letters, telegrams, poetry, and emails, begin to transcend time and the afterlife. Rich in gothic symbolism and emotional depth, the novel explores guilt, forgiveness, and redemption, with cinematic appeal for major retail and screen adaptation.
Los Angeles, CA - December…
Maple and Mocha Coffee's Holiday Campaign Brings Clean Water to Kirinda Village …
Emerging specialty roaster Maple and Mocha Coffee reports strong holiday season response to its Vermont Maple Pecan blend and clean water initiative. The company's commitment to donating 10% of sales to the Kyempapu Water Project resonates with gift-buyers seeking purpose-driven purchases during the festive season.
The intersection of holiday traditions and social responsibility has found a sweet spot in Maple and Mocha Coffee's Vermont Maple Pecan blend, as conscious consumers embrace…
Female Entrepreneur Disrupts Fashion Industry with Boutique Solving Women's Holi …
Fabulous Knits founder transforms personal shopping frustrations into thriving online boutique serving women 25-65 with unique, well-fitting fashion. The company's rapid growth in under two years demonstrates strong market demand for alternatives to generic retail offerings during peak holiday shopping periods.
In an industry dominated by mass-market retailers and unpredictable overseas suppliers, Fabulous Knits stands as a testament to the power of understanding and solving real customer problems. Founded by a…
Sarasota General Contractor Aegis Construction Services Responds to Growing Hurr …
Sarasota-based Aegis Construction Services expands hurricane restoration work, providing specialized foundation repairs and concrete services following the 2024 storm season across Florida's Gulf Coast.
Aegis Construction Services [http://www.aegisfl.com/] has seen increased demand for specialized construction services following the 2024 hurricane season that impacted Florida's Gulf Coast. The Sarasota-based company has been actively working on structural repairs and complete rebuilds for properties damaged by back-to-back storms.
Hurricane Recovery Projects Highlight Expertise
The company recently…
More Releases for Adrenocortical
Adrenocortical Carcinoma Treatment Market Diagnostic Improvements and Evolving T …
The Adrenocortical Carcinoma (ACC) Treatment Market is growing steadily as improvements in diagnostic imaging, surgical oncology, and targeted therapies enhance the management of this rare but aggressive endocrine malignancy. ACC often presents late and requires multimodal treatment including surgery, adrenalectomy, mitotane therapy, chemotherapy, and emerging immunotherapies. Rising clinical awareness, improved diagnostic accuracy, and expansion of cancer centers specializing in rare tumors are fueling demand for effective ACC treatments.
Download Full PDF…
Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033.
Adrenocortical Carcinoma Drugs Market Overview
The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,…
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this…
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc.
The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities…
